Low-dose Bacillus Calmette-Guerin versus full-dose for intermediate and high-risk of non-muscle invasive bladder cancer: a Markov model
Abstract Background To compare the efficacy of low dose (27 mg) Bacillus Calmette-Guérin (BCG) and a full dose (81 mg) BCG immunotherapy for patients with intermediate and high-risk non-muscle invasive bladder cancer (NMIBC) after a typical transurethral bladder resection. Methods We constructed a M...
Main Authors: | Zongren Wang, Han Xiao, Guangyan Wei, Ning Zhang, Mengchao Wei, Zebin Chen, Zhenwei Peng, Sui Peng, Shaopeng Qiu, Heping Li, Jianting Long |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-11-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-018-4988-z |
Similar Items
-
Bacillus Calmette–Guérin in Immuno-Regulation of Alzheimer’s Disease
by: Benjamin Y. Klein, et al.
Published: (2022-06-01) -
Interstitial pneumonitis secondary to intravesical bacillus calmette-guerin for carcinoma in-situ of the bladder
by: Eric K. Diner, et al.
Published: (2004-10-01) -
Late-onset granulomatous prostatitis following intravesical bacille Calmette-Guerin therapy: case report
by: Octavio Castillo Cádiz, et al.
Published: (2016-06-01) -
Intravesical bacillus Calmette–Guérin-induced myopathy presenting as rhabdomyolysis: a case report
by: Chae Hun Lee, et al.
Published: (2023-10-01) -
Impact of intravesical Bacillus Calmette-Guérin and chemotherapy on the bladder microbiome in patients with non-muscle invasive bladder cancer
by: Christopher James, et al.
Published: (2023-04-01)